When Will ESSA Pharma Inc. (NASDAQ:EPIX) Turn A Profit?

Simply Wall St.2024-12-21

We feel now is a pretty good time to analyse ESSA Pharma Inc.'s (NASDAQ:EPIX) business as it appears the company may be on the cusp of a considerable accomplishment. ESSA Pharma Inc., a clinical stage...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2493923070?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","is_english":true,"pubTime":"2024-12-21 20:59","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2493923070","market":"us","top_or_hot":-1,"title":"When Will ESSA Pharma Inc. (NASDAQ:EPIX) Turn A Profit?","media":"Simply Wall St.","content":"<div>\n<p>We feel now is a pretty good time to analyse ESSA Pharma Inc.'s (NASDAQ:EPIX) business as it appears the company may be on the cusp of a considerable accomplishment. ESSA Pharma Inc., a clinical stage...</p>\n\n<a href=\"https://finance.yahoo.com/news/essa-pharma-inc-nasdaq-epix-125919706.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>When Will ESSA Pharma Inc. (NASDAQ:EPIX) Turn A Profit?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhen Will ESSA Pharma Inc. (NASDAQ:EPIX) Turn A Profit?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-21 20:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/essa-pharma-inc-nasdaq-epix-125919706.html><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>We feel now is a pretty good time to analyse ESSA Pharma Inc.'s (NASDAQ:EPIX) business as it appears the company may be on the cusp of a considerable accomplishment. ESSA Pharma Inc., a clinical stage...</p>\n\n<a href=\"https://finance.yahoo.com/news/essa-pharma-inc-nasdaq-epix-125919706.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":".IXIC","symbol_name":"NASDAQ Composite","start_time":0,"source_url":"https://finance.yahoo.com/news/essa-pharma-inc-nasdaq-epix-125919706.html","article_id":"2493923070","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2493923070","pubTimestamp":1734785959,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"We feel now is a pretty good time to analyse ESSA Pharma Inc.'s  business as it appears the company may be on the cusp of a considerable accomplishment. ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The US$71m market-cap company announced a latest loss of US$29m on 30 September 2024 for its most recent financial year result. Many investors are wondering about the rate at which ESSA Pharma will turn a profit, with the big question being “when will the company breakeven?”Below we will provide a high-level summary of the industry analysts’ expectations for the company.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{".IXIC":"NASDAQ Composite","BK4585":"ETF&股票定投概念","BK4139":"生物科技","TQQQ":"纳指三倍做多ETF","BK4211":"区域性银行","BK4195":"互助储蓄与抵押信贷金融服务","BK4588":"碎股","ESSA":"萨万通金控","SQQQ":"纳指三倍做空ETF","QID":"纳指两倍做空ETF","USAW.SI":"AMZN 3xLongSG261006","TSYW.SI":"TESLA 3xLongSG261006","NVIW.SI":"NVDA 3xLongSG261006","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","EPIX":"ESSA Pharma Inc.","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4112":"金融交易所和数据","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","PSQ":"纳指反向ETF","USJW.SI":"ALPHAB 3xLongSG261006","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","QLD":"纳指两倍做多ETF","NDAQ":"纳斯达克OMX交易所","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC"},"translate_title":"ESSA Pharma Inc.（纳斯达克股票代码：EPIX）何时扭亏为盈？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EPIX":1,"ESSA":1,"NDAQ":1,".IXIC":1,"USJW.SI":0.6,"USAW.SI":0.6,"TSYW.SI":0.6,"TQQQ":0.6,"SQQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"NVIW.SI":0.6,"NQmain":0.6,"MNQmain":0.6},"content_text":"We feel now is a pretty good time to analyse ESSA Pharma Inc.'s (NASDAQ:EPIX) business as it appears the company may be on the cusp of a considerable accomplishment. ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The US$71m market-cap company announced a latest loss of US$29m on 30 September 2024 for its most recent financial year result. Many investors are wondering about the rate at which ESSA Pharma will turn a profit, with the big question being “when will the company breakeven?” Below we will provide a high-level summary of the industry analysts’ expectations for the company. \n View our latest analysis for ESSA Pharma \n Consensus from 4 of the American Biotechs analysts is that ESSA Pharma is on the verge of breakeven. They anticipate the company to incur a final loss in 2026, before generating positive profits of US$26m in 2027. The company is therefore projected to breakeven around 3 years from now. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 46% is expected, which is extremely buoyant. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict. \n\n\n\n  NasdaqCM:EPIX Earnings Per Share Growth December 21st 2024\n \n\n Given this is a high-level overview, we won’t go into details of ESSA Pharma's upcoming projects, however, keep in mind that generally a biotech has lumpy cash flows which are contingent on the product type and stage of development the company is in. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments. \n Before we wrap up, there’s one aspect worth mentioning. ESSA Pharma currently has no debt on its balance sheet, which is quite unusual for a cash-burning biotech, which usually has a high level of debt relative to its equity. This means that the company has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company. \nNext Steps:\n There are key fundamentals of ESSA Pharma which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at ESSA Pharma, take a look at ESSA Pharma's company page on Simply Wall St. We've also compiled a list of important factors you should further research: \n\nValuation: What is ESSA Pharma worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether ESSA Pharma is currently mispriced by the market.\nManagement Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on ESSA Pharma’s board and the CEO’s background.\nOther High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.\n\nHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2493923070"}